Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

PMCB - PharmaCyte Biotech Inc


IEX Last Trade
1.535
-0.035   -2.280%

Share volume: 5,898
Last Updated: Fri 30 Aug 2024 09:58:56 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$1.57
-0.04
-2.23%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-7.83%
1 Month
-23.50%
3 Months
-24.26%
6 Months
-27.14%
1 Year
-37.30%
2 Year
-41.83%
Key data
Stock price
$1.54
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$1.39 - $2.63
52 WEEK CHANGE
-$0.38
MARKET CAP 
11.795 M
YIELD 
N/A
SHARES OUTSTANDING 
7.709 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.68
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$18,565
AVERAGE 30 VOLUME 
$14,824
Company detail
CEO:
Region: US
Website: pharmacyte.com
Employees: 2
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

pharmacyte biotech, inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the united states. its cellular therapies are developed based on cell-in-a-box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. the company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the activation of cancer-killing drugs to the source of the cancer. it is also developing a therapy for type 1 diabetes and insulin-dependent type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. pharmacyte biotech, inc. has a research agreement with the university of technology, sydney to create a version of melligen cells to treat diabetes; and a research agreeme

Recent news